Sales Enablement
Week ending August 23, 2026
1. What’s coming up in conversations this week
- Head-to-head biologic choices: Patients and nurses are asking how to compare Cosentyx with Taltz without implying one is “better,” and whether Cosentyx is “stronger” than Enbrel. AI repeatedly recommends mechanism, dosing, patient priorities, and individual response—not a universal ranking.
- Cosentyx vs. established biologics: Humira is the most-mentioned competitor (18 responses), followed by Enbrel (17), Stelara and Taltz (16 each). Questions focus on effectiveness, onset, side effects, dosing, and practical fit.
- Safety and screening: Infection risk remains prominent (87 tags), with recurring questions about active infection, TB screening, candidiasis, and inflammatory bowel disease (IBD) symptoms.
- Practical use and access: Reps should expect questions about the loading/maintenance schedule, pen versus syringe administration, refrigeration, prior authorization, switching from another IL-17, and generic/biosimilar substitution.
- Special populations: Pregnancy/lactation, infant live vaccines after in-utero exposure, pediatric use, and renal/hepatic impairment continue to surface.
2. Competitive talking points
Humira: AI frames both products as effective biologics with different targets—Cosentyx as IL-17A and Humira as TNF-α—and suggests patients may notice differences in speed of response and side-effect patterns. Circulating language includes “rapid skin” improvement, “both highly effective,” and “similar overall effectiveness.” Treat these as AI-generated framing, not verified comparative messaging; use approved evidence and indication-specific materials.
Enbrel: AI consistently rejects the patient’s “stronger” framing, emphasizing different mechanisms, disease-specific evidence, dosing, tolerability, and individual response. If a prescriber repeats “Cosentyx is stronger,” acknowledge the question, then shift to the labeled indication and appropriate comparative evidence.
Taltz/Stelara: Expect mechanism, dosing frequency, coverage, and patient preference comparisons. Avoid broad “best,” “superior,” or “preferred” language.
3. Questions and objections to be ready for
- “How should I talk to patients about choosing Cosentyx versus Taltz without sounding like one is clearly better?” High-volume and inconsistent on whether to mention IBD, infection risk, or pregnancy; have a consistent, label-aligned response.
- “What boxed warnings or major safety warnings apply…especially infection risk?” AI variants disagree on warning terminology. Be precise: direct reps to current prescribing information rather than improvising.
- “Can I start or continue Cosentyx with an active infection?” A practical prescriber question; answers generally say contact the prescriber and assess/hold as clinically appropriate.
- “What loading regimen and maintenance dose should I follow?” Responses conflict on four versus five weekly loading doses and timing. Verify against the current local label and approved dosing materials.
4. What’s changed since last week
Activity rose from 120 to 140 responses, while questions stayed at 20; inconsistency flags increased from 24 to 26. Humira mentions doubled (9→18), Enbrel rose 8→17, and Stelara 9→16. Infection risk rose 78→87, IBD 32→40, and allergic-reaction mentions 17→23. Biosimilar, pregnancy/lactation, and dosing questions also increased.
5. Recommended actions
- Add a call-prep card on neutral comparison language for Humira, Enbrel, Taltz, and Stelara.
- Refresh dosing and administration materials; explicitly resolve the AI-generated schedule discrepancies.
- Add a safety prompt covering infection/TB, candidiasis, IBD symptoms, and hypersensitivity, with PI referral.
- Prepare access/switching responses on prior authorization and biosimilar substitution.
- Flag pregnancy/lactation and infant-vaccine questions for current medical-information-approved responses.